The overall goal of the proposed research is to develop orally active inhibitors of myeloperoxidase MPO as a treatment forAlzheimer's disease. MPO is an abundant enzyme in leukocytes but its expression can be induced in astrocytes in Alzheimer's disease. This abnormal expression of MPO can lead to the oxidation of lipids and proteins leading to tissue damage and cell death resulting in loss of memory. A potent and safe inhibitor of MPO could be helpful in the treatment of Alzheimer's disease. We have developed novel mouse model to evaluate the role of MPO in Alzheimer's disease.
In Specific Aim 1 We propose to improve the potency of hits identified in a screen looking for inhibitors of MPO.
In Specific Aim 2 we propose to test several of the MPO inhibitors in a mouse model of Alzheimer's disease. The mice will be evaluated using both biochemical and behavioral/cognitive tests.
Myeloperoxidase is recognized as an important causative contributory agent in inflammatory diseases including Alzheimer's disease. An inhibitor of myeloperoxidase would provide a novel therapeutic agent that could be used to lower the level of oxidative damage that occurs in Alzheimer's disease. The experiments outlined in this Phase I SBIR application will help set the stage for the development of a novel and safe myeloperoxidase inhibitor for clinical use.
|Delporte, Cédric; Zouaoui Boudjeltia, Karim; Furtmüller, Paul G et al. (2018) Myeloperoxidase-catalyzed oxidation of cyanide to cyanate: A potential carbamylation route involved in the formation of atherosclerotic plaques? J Biol Chem 293:6374-6386|
|Laura, Richard P; Dong, David; Reynolds, Wanda F et al. (2016) T47D Cells Expressing Myeloperoxidase Are Able to Process, Traffic and Store the Mature Protein in Lysosomes: Studies in T47D Cells Reveal a Role for Cys319 in MPO Biosynthesis that Precedes Its Known Role in Inter-Molecular Disulfide Bond Formation. PLoS One 11:e0149391|